INTERFERON ALFA-2B
Stage IV Renal Cell Cancer
University of Aarhusprotein_peptidePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Stage IV Renal Cell Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib CCTU- Cancer Theme | Phase 3 | BB |
FLUDEOXYGLUCOSE Rahul Aggarwal | Phase 2 | BB |
Tas-102 Exelixis | Phase 3 | BB |
Vorinostat Nabil Adra | Phase 2 | BB |
gp100 antigen National Cancer Institute (NCI) | Phase 2 | B |
View all 12 →
Same molecule, other indications
INTERFERON ALFA-2B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →